Skip to content
10-K

Annual Report

Janux Therapeutics, Inc. JANX

0000950170-25-029177

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 25, 2025 59.11M sh
Short Term Investments FY 2024 · Dec 31, 2023 $324.82M
Cash And Equivalents FY 2024 · Dec 31, 2023 $19.21M
Current Liabilities FY 2024 · Dec 31, 2023 $13.03M
Total Liabilities FY 2024 · Dec 31, 2023 $36.06M
Current Assets FY 2024 · Dec 31, 2023 $349.24M
Total Assets FY 2024 · Dec 31, 2023 $380.41M
Shares Diluted FY 2024 · Dec 31, 2022 41.47M sh
Capex FY 2024 · Dec 31, 2022 $6.45M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$42.92M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.52
Eps Basic FY 2024 · Dec 31, 2022 −$1.52
Sga Expense FY 2024 · Dec 31, 2022 $22.26M
Rd Expense FY 2024 · Dec 31, 2022 $53.44M
Net Income FY 2024 · Dec 31, 2022 −$63.06M
Operating Income FY 2024 · Dec 31, 2022 −$67.09M
Revenue FY 2024 · Dec 31, 2022 $8.61M
Stockholders Equity FY 2024 · Dec 31, 2021 $366.33M